Pay in 4 interest-free payments of $6.12 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
Implications for practice Following more than 6 months where initiation of GLP-1 RAs was not permitted in the UK, clinicians will have been pleased to read the National Drug Safety Alert published earlier this month, which confirms that there are now sufficient supplies of daily oral semaglutide (Rybelsus) available in the UK to allow new initiations as well as supplying those already on treatment
Dose increases follow a clinician-directed schedule
Generally, individuals eligible for semaglutide typically have a body mass index (BMI) of 27 or higher and at least one weight-related condition
When compared head-to-head with semaglutide in the SURPASS 2 trial, nausea was reported in 1722% of patients who received tirzepatide, and in 18% who received semaglutide
:max_bytes(150000):strip_icc()/sulfa-vs-sulfites-list-of-sulfa-drugs-and-sulfite-foods-5324710-TEXT-FINAL-1-f9c48938262b4a73ba7d1c6f9816f932.png)
